Skip to main content

Table 2 Post-exercise outcomes compared to baseline

From: Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial

Outcome

N

 

T0 (Base)

T1 (15 Min.)

T2 (90 Min.)

T3 (1 Day)

T4 (2 Day)

8OHdG (ng/mL)

22

Mean ± SD

9.06 ± 3.28

10.59 ± 4.00

10.25 ± 3.57

8.60 ± 2.98

8.50 ± 2.50

ΔBaseline

 

1.53**

(0.86–2.20)

1.19*

(0.37–2.01)

−0.46

(−1.18–0.26)

−0.57

(−1.27–0.13)

MDA (μM)

22

Mean ± SD

17.4 ± 4.7

24.7 ± 7.7

18.3 ± 6.1

16.2 ± 4.3

17.3 ± 4.7

ΔBaseline

 

7.3**

(3.9–10.7)

0.9

(−1.8–3.6)

−1.2

(−2.9–0.5)

−0.1

(−2.2–1.9)

logCK (U/L)

22

Mean ± SD

1.99 ± 0.20

2.25 ± 0.26

2.32 ± 0.28

2.58 ± 0.46

2.35 ± 0.42

ΔBaseline

 

0.26**

(0.13–0.38)

0.33**

(0.20–0.46)

0.59**

(0.39–0.79)

0.36**

(0.17–0.54)

LDH (U/L)

22

Mean ± SD

158.2 ± 18.9

230.4 ± 41.3

232.4 ± 48.0

188.4 ± 31.9

180.1 ± 35.1

ΔBaseline

 

72.2**

(54.6–89.8)

74.2**

(53.9–94.6)

30.2**

(17.0–43.4)

21.9*

(8.1–35.7)

Muscle Pain (mm)

21

Mean ± SD

15.3 ± 20.6

38.6 ± 25.6

33.6 ± 27.6

36.2 ± 25.3

21.4 ± 21.1

ΔBaseline

 

23.3**

(11.6–35.1)

18.3*

(5.7–31.0)

20.9**

(9.3–32.5)

6.2

(−3.5–15.9)

Joint Pain (mm)

21

Mean ± SD

8.7 ± 19.3

33.5 ± 21.3

31.2 ± 25.2

23.9 ± 23.2

16.4 ± 26.2

ΔBaseline

 

24.8**

(15.0–34.6)

22.5**

(10.9–34.0)

15.2*

(4.6–25.9)

7.7

(−4.3–19.7)

  1. Results adjusted for mean-centered baseline. Means reported with standard deviations. ΔBaseline indicates the change from baseline (T0) – reported with 95% confidence interval. *P < 0.01 vs baseline. **P < 0.001 vs baseline